Cim 2024 Recifercept

Cim 2024 Recifercept. We're sorry, this event is now closed. Recifercept is the most advanced rare disease candidate to become discontinued.


Cim 2024 Recifercept

Today pfizer announced that the first participants were dosed in the global phase 2 multiple dose, randomized study to assesses the safety, tolerability, pharmacokinetics, and. Cim’s annual convention inspires, educates, and unites mining professionals for an extensive plenary & technical program, an innovative expo, and reputable networking and.

Cim 2024 Recifercept Images References :